{
    "medicine_id": "7ac14cbcb21af4b6b5d4f0ee3c2973c644ea611b",
    "platform_id": "DB05540",
    "metadata": {
        "name": "Kynamro 200 mg 1mL Injection solution",
        "composition": "200 mg 1mL Alanosine",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in brain cancer and cancer tumors unspecified",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alanosine"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alanosine"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Alanosine"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Alanosine"
                    },
                    {
                        "drugbank-id": "DB09139",
                        "description": "Alanosine may decrease effectiveness of Technetium Tc 99m oxidronate as a diagnostic agent"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}